

NOV 17 2005

PAGE 1/6 • RCV'D AT 11/17/2005 4:35:04 PM [Eastern Standard Time] • SVR:USPTO-EXPRESS-6/28 • DMS:2738300 • CSID:17813947778 • DURATION (mm:ss):03-32



Insulet Corporation  
9 Oak Park Drive  
Bedford, MA 01730  
Tel: 781-457-5000  
Fax: 781-457-5011  
[www.MyOmniPod.com](http://www.MyOmniPod.com)

## Fax Cover Sheet

Confidential

To: Dr. Roz Maiorino

From: R. Anthony Diehl

Company: US PTO

Pages: 6

Fax: 571-273-8300

Date: 11/17/2005

Telephone:

CC:

Re: U.S. App. Ser. No. 10/695547; Conf. No. 5464; Atty. Dckt. No. INSL-0110CN

**Comment:** THIS IS A DUPLICATE SUBMISSION. THE PREVIOUS SUBMISSION CONTAINED AN ERROR IN THE SERIAL NUMBER LISTED ABOVE.

Insulet Corporation

RECEIVED  
CENTRAL FAX CENTER

NOV 17 2005

PAGE 2/6 · RCV'D AT 11/17/2005 4:35:04 PM [Eastern Standard Time] · SVR:USPTO-EFXR-F-6/28 · DINS:2738300 · CSID:1781394778 · DURATION (mm:ss):03:32

**AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111**  
Serial Number: 10/695,547  
Filing Date: October 28, 2003  
Title: Devices, Systems and Methods for Patient Infusion

Page 1  
Dkt: INSL-0110CN

**S/N 10/695,547**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: J. Christopher Flaherty                      Examiner: Maiorino, R.  
Serial No.: 10/695,547                                  Group Art Unit: 3763  
Filed: October 28, 2003                                  Docket No.: INSL-0110CN  
Title: Devices, Systems and Methods for Patient Infusion

**AMENDMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Applicant has reviewed the Office Action mailed on 5/18/2005.

This response is accompanied by a Petition, as well as the appropriate fee, to obtain a 3-month extension of the period for responding to the Office action, thereby moving the deadline for response to 11/18/2005.

Please amend the above-identified patent application as follows.

- Amendments to the claims are reflected in the listing of claims that begins on page 2 of this paper;
- Remarks begin on page 4 of this paper.